Immunotherapy may replace chemo in head and neck cancer trial
NCT ID NCT03383094
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 36 times
Summary
This study tests whether the immunotherapy drug pembrolizumab (Keytruda) combined with radiation works better than the standard chemotherapy drug cisplatin with radiation for patients with a certain type of head and neck cancer (p16-positive). About 126 adults with advanced or intermediate-risk cancer will be randomly assigned to one of the two treatments. The main goal is to see which approach helps patients live longer without their cancer coming back, while also monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center & Research Facility
Tampa, Florida, 33612, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
University of Arizona Cancer Center
Tucson, Arizona, 85719, United States
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37203, United States
-
Washington University School of Medicine, Siteman Cancer Center
St Louis, Missouri, 63110, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.